ROCHE-NV15942

Study Sponsor : Roche

Study Title

A phase III, randomized, multicenter, efficacy and safety study examining the effects of the duration of treatment and the daily dose of ribavirin in patients with chronic hepatitis C virus infection treated with the combination of pegylated-interferon alpha-2a and ribavirin

Medicine or Vaccine (generic name)

peg-interferon alpha-2a

Sponsor Identification Number

NV15942

Trial Registry Identification Number(#'s)

Medical Condition

chronic hepatitis c

Phase

Phase 3

Link to study details on the Roche Clinical Study Register

Link to study details on ClinicalTrials.gov (if available)

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

January 2014